Spanish cancer biomarker medtech Reveal Genomics has boosted the roles of three of its founding members. | Spanish cancer biomarker medtech Reveal Genomics has boosted the roles of three of its ...
Qilu Pharmaceutical has struck a deal to tap into Insilico Medicine’s artificial intellige | Qilu Pharmaceutical has struck a ...
When Genenta Science listed on the Nasdaq at the tail-end of 2021, the Milan, Italy-based biotech was squarely focused on its pipeline of cell-based gene therapies. | Four years after listing on the ...
European investment firm Gimv will no longer put funds into the life sciences sector, choosing instead to focus on its ...
United Therapeutics’ bioengineered external liver assist system developed to treat patients with acute forms of chronic liver failure proved promising based on ...
Portland, Oregon-based startup Oath Surgical is partnering with tech giant Nvidia to enhance Oath’s artificial-intelligence-powered outpatient surgery center operating system. | Portland, Oregon-based ...
Roche’s dual GLP-1/GIP receptor agonist has been tied to 22.5% weight loss at 48 weeks, validating the company’s decision to move the asset into phase 3 studies this quarter.
Boehringer Ingelheim has penned a 1.05 billion euro ($1.26 billion) biobucks deal for Simcere’s preclinical inflammatory bowel disease (IBD) bispecific antibody. | Boehringer Ingelheim has penned a 1.
The ex-CytoDyn chief exec must also forfeit more than $4.4 million—approximately the amount he profited from the scheme—and ...
What do you get when you insert a molecular glue degrader into an antibody-drug conjugate (ADC)? Fortitude Biomedicines is in ...
The industry has learned how the ball bounces—now it must decide where to play next.  | While 2025 was dedicated to “understanding a little bit more about the rules of this game that we’re playing,” ...
AstraZeneca is showing no signs of restarting a 200 million pound sterling ($273 million) investment in its U.K. hometown, despite keeping its options open. | AstraZeneca is showing no signs of ...